Late-stage IDENTITY study of once-daily, oral agent is now enrolling
Eli Lilly and Company
(NYSE: LLY) has announced today the start of a Phase III clinical trial
studying LY450139, an investigational gamma secretase inhibitor for the
treatment of mild to moderate Alzheimer’s disease.
Slowing the rate of disease progression could preserve independent
functioning and quality of life for Alzheimer’s patients in the milder
stages of the disease, potentially delaying the onset of the severe stages
of the disease.
LY450139 is being tested
to see if it can slow the progression associated with Alzheimer’s disease
by inhibiting gamma-secretase, an enzyme that can create a sticky protein
called amyloid beta.
IDENTITY is a randomized, double-blind, placebo-controlled trial that
will be conducted in the U.S. and 21 additional countries.
information regarding the IDENTITY trial, including global
recruitment sites, may be found at clinicaltrials.gov